TTP LabTech Announce US Expansion to Meet Growing Customer Demand
News Jul 30, 2007
TTP LabTech has announced the further expansion of its US facilities with the recruitment of sales and customer service personnel for its East Coast office in Cambridge, MA.
Driven by increasing sales of mosquito®, comPOUND® and Acumen® eX3, TTP LabTech has recruited Doug Mann to its support division as a Field Service Engineer.
Doug brings with him many years of automation experience and joins the US Sales & Support Manager, Ben Schenker, recently relocated from the company’s UK headquarters.
TTP LabTech Inc’s new US headquarters in Cambridge, MA, will serve to support customer needs and the increasing demand for TTP LabTech products in North America. This announcement follows the recent appointment of distributors in Japan, India and Australia, demonstrating TTP LabTech’s growing customer appeal and global outreach.
According to Ben Schenker, “TTP LabTech is celebrating 20 years in automation in 2007. This, along with our greatly increased worldwide presence and expanded US office, makes it a very exciting time for the company and the response from customers has been tremendous”.
Commercial Director, Jas Sanghera, says the US expansion has been fuelled by customer demand for TTP LabTech’s wide range of innovative instrumentation and excellent technical expertise. “We have wanted to expand our team of highly qualified scientists and engineers to support the life science hubs on the East Coast and are delighted to have such an experienced team on board.”
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.